NCT01213680已完成1 期
Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer)Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Total serum iron pharmakokinetic parameters
研究概览
简要总结
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women, aged more than 18 years
- •Subjects diagnosed with inflammatory bowel disease and mild to moderate disease activity (defined as a score of less than or equal to 5 on the Harvey-Bradshaw index for Crohn's disease and a Mayo score (subscore without endoscopy) of less than or equal to 6 for ulcerative colitis)
- •Weight above 50 kg
- •Hb <12 g/dL (7.45 mmol/L)
- •Transferrin saturation (TfS) <20%
- •Life expectancy beyond 12 months by investigator's judgment
- •Willingness to participate after informed consent -
排除标准
- •Anaemia predominantly caused by other factors than iron deficiency anaemia
- •Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
- •Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or disaccharide complexes or to iron sulphate)
- •Known hypersensitivity to any excipients in the investigational drug products
- •Subjects with a history of multiple allergies
- •Active Intestinal Tuberculosis
- •Active intestinal amoebic infections
- •Decompensated liver cirrhosis and hepatitis (Alanine Aminotransferase (ALT) > 3 times upper limit normal)
- •History of immunocompromise and/or history of Hepatitis B and/or C
- •Acute infections (assessed by clinical judgment), supported by white blood cells (WBC) and C-reactive protein (CRP))
- •Rheumatoid arthritis with symptoms or signs of active joint inflammation
- •Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following contraceptives during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, intrauterine devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches)
- •Extensive active bleeding necessitating blood transfusion
- •Planned elective surgery during the study
- •Participation in any other clinical study within 3 months prior to screening
- •Untreated B12 or folate deficiency
- •Other I.V. or oral iron treatment or blood transfusion within 4 weeks prior to screening visit
- •Erythropoietin treatment within 4 weeks prior to screening visit
- •Any other medical condition that, in the opinion of Investigator, may cause the patient to be unsuitable for the completion of the study or place the patient at potential risk from being in the study. Example: Uncontrolled Hypertension, Unstable Ischemic Heart Disease or Uncontrolled Diabetes Mellitus
研究组 & 干预措施
1000 mg iron isomaltoside as intravenous infusion
Active Comparator
干预措施: Monofer (iron isomaltoside 1000) (Drug)
500 mg iron isomaltoside 1000 as bolus injection
Active Comparator
干预措施: Monofer (Drug)
结局指标
主要结局
Total serum iron pharmakokinetic parameters
时间窗: 24, 48 and72 hours
次要结局
- Total urine-iron pharmakokinetic parameters(24, 48 and 72 hours)
研究者
相似试验
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)Non-hematological MalignanciesNCT01213979Pharmacosmos A/S16
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKDNon-dialysis Dependent Chronic Kidney DiseaseNCT01213992Pharmacosmos A/S16
已完成
1 期
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)Chronic Kidney DiseaseNCT01469078Pharmacosmos A/S18
已完成
1 期
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced AnaemiaPatients With Chemotherapy Induced Anemia (CIA)NCT01280240Pharmacosmos A/S11
已完成
1 期
Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron DeficiencyIron Deficiency, Anaemia in ChildrenIron-DeficiencyNCT03181451Shield Therapeutics37